Sum­it­o­mo sub­sidiary flash­es new way of treat­ing schiz­o­phre­nia in PhII tri­al

A US-based sub­sidiary of Japan­ese phar­ma gi­ant Sum­it­o­mo is tout­ing the mid-stage re­sults of a schiz­o­phre­nia drug they say of­fers a new way to treat the long-elu­sive dis­or­der, po­ten­tial­ly help­ing stem an en­tire set of symp­toms that have gone un­mit­i­gat­ed un­der cur­rent ther­a­pies.

In a Phase II study of 245 ear­ly stage schiz­o­phre­nia pa­tients, pub­lished to­day in the New Eng­land Jour­nal of Med­i­cine, those giv­en a pill called SEP-363856 im­proved 17.2 points on av­er­age on the Pos­i­tive and Neg­a­tive Syn­drome Scale used to as­sess schiz­o­phre­nia symp­toms. That com­pared to a 9.7 point im­prove­ment for the place­bo group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.